These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 15720781)

  • 1. A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies.
    Evans L; Aarons L; Brearley C
    J Pharm Pharmacol; 2005 Feb; 57(2):183-9. PubMed ID: 15720781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.
    Jauregizar N; de la Fuente L; Lucero ML; Sologuren A; Leal N; Rodríguez M
    Clin Pharmacokinet; 2009; 48(8):543-54. PubMed ID: 19705924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
    Deschamps C; Dubruc C; Mentre F; Rosenzweig P
    Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients.
    Mould D; Chapelsky M; Aluri J; Swagzdis J; Samuels R; Granett J
    Clin Pharmacol Ther; 2001 Apr; 69(4):210-22. PubMed ID: 11309549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
    Trocóniz IF; de Alwis DP; Tillmann C; Callies S; Mitchell M; Schaefer HG
    Clin Pharmacol Ther; 2000 Jul; 68(1):18-27. PubMed ID: 10945312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of H1- and H2-antihistamines on platelet-activating factor and bradykinin-induced inflammatory responses in human skin.
    Sansom JE; Brooks J; Burton JL; Archer CB
    Clin Exp Dermatol; 1996 Jan; 21(1):33-7. PubMed ID: 8689766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
    Brecht HM; Adamus WS; Heuer HO; Birke FW; Kempe ER
    Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen.
    Kuitert LM; Hui KP; Uthayarkumar S; Burke W; Newland AC; Uden S; Barnes NC
    Am Rev Respir Dis; 1993 Jan; 147(1):82-6. PubMed ID: 8420437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans.
    O'Connor BJ; Uden S; Carty TJ; Eskra JD; Barnes PJ; Chung KF
    Am J Respir Crit Care Med; 1994 Jul; 150(1):35-40. PubMed ID: 8025768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers.
    Barbanoj MJ; García-Gea C; Morte A; Izquierdo I; Pérez I; Jané F
    Neuropsychobiology; 2004; 50(4):311-21. PubMed ID: 15539863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
    Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
    Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males.
    Church MK
    Br J Dermatol; 2010 Dec; 163(6):1330-2. PubMed ID: 20819087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
    Herbert JM; Laplace MC; Maffrand JP
    J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans.
    Billah MM; Gilchrest HG; Eckel SP; Granzow CA; Lawton PJ; Radwanski E; Brannan MD; Affrime MB; Christopher JD; Richards W
    Clin Pharmacol Ther; 1992 Aug; 52(2):151-9. PubMed ID: 1505150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine.
    Urien S; Tillement JP; Ganem B; Kuch MD
    Int J Clin Pharmacol Ther; 1999 Oct; 37(10):499-502. PubMed ID: 10543317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.